Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiotech steps up CardioPass development:

This article was originally published in Clinica

Executive Summary

Cardiotech International is pressing ahead with a preclinical research programme to assess its synthetic coronary artery bypass graft after early study data confirmed that the product had acceptable handling characteristics and potential for clinical use. The CardioPass graft is manufactured from the company's ChronoFlex biodurable polyurethane polymer. Cardiotech predicts that animal studies of the graft could start early next year, followed by human trials around mid-2003. The firm Woburn, Massachusetts, firm estimates that heart bypass surgery represents a market opportunity of $1.5 billion for synthetic grafts.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel